CD8A and myeloid sarcoma: As illustrated on the regulatory side – to which our lab has made several novel contributions – several lines of evidence exist demonstrating the regulatory mechanisms performed by CD8+ T-cells in the context of MS/EAE, which can either be neuroantigen specific (MHC class 1a-restricted) or GA/Copaxone® specific (HLA-E/Qa-1-restricted).